NOT FDA-APPROVED

TB-500 (Thymosin Beta-4)

The other half of the Wolverine stack · paired with BPC-157

Almost always discussed alongside BPC-157 in the WOLVERINE recovery blend. A synthetic fragment of a naturally occurring repair protein, studied for soft-tissue healing. Solo TB-500 use exists but is uncommon outside dedicated tendon-injury research.

The 30-second read

TB-500 is a synthetic version of the active region of Thymosin Beta-4, a protein your body already makes, it's involved in cell migration, wound healing, and forming new blood vessels in injured tissue. Researchers and athletes pay attention to it because animal studies suggest it speeds up soft-tissue repair: muscle, tendon, ligament. It's almost always paired with BPC-157, where the two peptides handle different parts of the healing process. It's not FDA-approved. Human evidence is thin, most of what we know is from animal models, and from anecdote. It's on the FDA's Category 2 list (since September 2023) and on the World Anti-Doping Agency banned list. The April 2026 FDA panel review of compounded peptides included TB-500 alongside BPC-157.

Why this peptide is on people's radar

TB-500's profile in the wider peptide conversation comes almost entirely from one place: it's paired with BPC-157 in the "Wolverine stack." Joe Rogan helped name and popularize that pairing on his podcast. Athletes recovering from significant injuries. Jeremy Renner, NFL retirees, Olympic-level competitors who've talked openly about peptides, frequently include both BPC-157 and TB-500 (or its parent protein, Thymosin Beta-4) in the protocols they describe.

The mechanistic story is what makes the pairing make sense to clinicians. BPC-157 has been studied for promoting new blood vessel formation and growth-factor signaling in injured tissue. TB-500 (more accurately, the synthetic Thymosin Beta-4 fragment behind it) has been studied for cell migration, getting the cells that need to be at the injury site to actually move there. The argument for using them together is that they cover different parts of the same healing process.

The April 2026 FDA Pharmacy Compounding Advisory Committee review of seven compounded peptides included both BPC-157 and TB-500 in scope. That review is happening on the back of public advocacy from HHS Secretary Robert F. Kennedy Jr. The panel's recommendation is advisory; the FDA retains the final decision. But the fact that it's happening at all has changed the regulatory conversation around both peptides.

What people are usually trying to do with it

People exploring TB-500 are usually focused on:

Recovering from a muscle tear, strain, or pull that hasn't fully healed
Healing a tendon or ligament injury alongside BPC-157
Improving flexibility, range of motion, and reducing stiffness
Bouncing back from training or surgery
Calming a chronically inflamed tissue or joint

What the science actually shows

TB-500 (and the parent Thymosin Beta-4 protein) has decades of preclinical research. The human side is much thinner. Plain-English summary:

Wound healing

Animal and in-vitro studies consistently show faster wound closure, more new blood-vessel formation, and improved tissue quality with Thymosin Beta-4 treatment. A small set of human Phase 2 trials in chronic wounds has shown promise but did not lead to FDA approval.1 2

Soft-tissue repair (tendon, ligament, muscle)

Rodent studies of muscle tears, ligament injuries, and tendon damage report faster repair and better tissue mechanics. There are no rigorous human RCTs in soft-tissue injury.3

Cardiac repair

Some preclinical heart-injury models show that Thymosin Beta-4 may protect cardiac tissue and support repair after damage. Early human trials in cardiology did not produce results strong enough to advance.4

Anti-inflammatory effects

Cell-culture and animal studies report reductions in inflammatory markers in injured tissues, consistent with the broader "promotes healthy healing" picture.5

What it has not been shown to do

Reliably treat any specific human injury or condition in a randomized controlled trial. Be safe over months or years of use. Substitute for proper rehab, most of the people getting good results report doing physical therapy alongside.

The honest read

What's solid:

The animal and lab evidence for Thymosin Beta-4 (the parent protein) is consistent across decades and labs. The cell-migration mechanism is well-characterized. The mechanistic complementarity with BPC-157 is plausible.

What's still unproven:

Human evidence for the soft-tissue-injury use case (the one most people care about) is mostly anecdotal. The Phase 2 wound-healing trials with the parent protein were promising but did not lead to approval. Long-term safety is not characterized.

What's hyped beyond the evidence:

Claims that TB-500 "regenerates" damaged tissue in humans, that the Wolverine stack is a clinically established treatment, or that it dramatically outperforms physical therapy alone. The animal data is interesting; it isn't clinical proof.

Things to know if you're looking into it

How it's used in research: typically a subcutaneous injection one or two times per week, often near the injured area. Doses are larger and frequency lower than BPC-157 because the peptide is studied at a longer-acting profile.
Almost always paired with BPC-157: the "Wolverine stack" is the most common framing. The two peptides are studied for different parts of the same healing process. BPC-157 for new blood-vessel formation and growth-factor effects, TB-500 for cell migration.
Regulatory status: not FDA-approved. Added to the FDA Category 2 list in September 2023, alongside BPC-157, making it ineligible for licensed-pharmacy compounding. The April 2026 FDA advisory panel review of compounded peptides included TB-500.
Athlete bans: TB-500 (and Thymosin Beta-4 more broadly) is on the World Anti-Doping Agency banned list and the NCAA's prohibited-substance list. Competitive athletes will test positive.
Healthcare provider involvement: a licensed clinician should be part of any decision about use. Soft-tissue injuries especially benefit from a proper diagnosis before considering anything else.
Specific dosing protocols, mechanism, half-life, and full reference list: all in the "Want to go deeper?" section below.

What people often ask

Is TB-500 the same as Thymosin Beta-4?

Almost. TB-500 is a synthetic 17-amino-acid fragment of the larger 43-amino-acid Thymosin Beta-4 protein, designed to capture the active region. Most preclinical research that gets cited for TB-500 was actually done on the full Thymosin Beta-4 protein, which is part of why the evidence-base discussion gets confusing.

Is it safer than BPC-157?

Both have similarly thin human safety data. Neither has been studied long-term in healthy adults. Most reports of side effects are mild and anecdotal. Comparing safety profiles in any meaningful way isn't possible without actual head-to-head trials, which haven't been done.

How is the Wolverine stack typically used in research?

Reported research-community pairings combine BPC-157 (around 250–500 mcg daily) with TB-500 (around 2–5 mg, given once or twice weekly). There are zero published human studies of this combination, anyone making strong claims about its effectiveness is extrapolating.

Will it help my torn rotator cuff / hamstring / Achilles?

The animal data suggests that something like that might be possible. The human data does not yet exist. People who report good outcomes anecdotally are usually doing serious physical therapy alongside, which makes the contribution of any peptide hard to isolate.

Is it banned for athletes?

Yes. TB-500 and Thymosin Beta-4 are on the World Anti-Doping Agency banned list and NCAA prohibited substances. Competitive athletes will test positive.

What's the FDA reviewing in 2026?

The Pharmacy Compounding Advisory Committee meeting on July 23–24, 2026, is reviewing whether seven peptides (including BPC-157 and TB-500) should be removed from the Category 2 list and made available for compounding. The committee's recommendation is advisory; the FDA retains the final decision authority.

FDA and regulatory status

⚡ Regulatory update. April 15, 2026

The FDA announced it will convene the Pharmacy Compounding Advisory Committee on July 23–24, 2026 to review whether TB-500, alongside BPC-157 and five other peptides, should be removed from the Category 2 list and made available for compounding. The panel's recommendation is advisory, the FDA retains final decision authority. Sources: FDA.gov, STAT News.

Status as of May 5, 2026: Not FDA-approved for any medical indication. Added to the FDA Category 2 list in September 2023, making it ineligible for compounding by licensed pharmacies under standard pathways. Listed on the World Anti-Doping Agency Prohibited List. Status updates land here when they happen.

Notable commentary

TB-500 sits in BPC-157's mainstream-conversation slipstream. The same cast of characters tends to come up.

Joe Rogan and the Wolverine stack

The "Wolverine stack" framing for the BPC-157 + TB-500 combination has been pushed into mainstream awareness largely through repeated discussion on The Joe Rogan Experience. Mainstream coverage has noted his influence while flagging that human clinical evidence for either peptide remains limited.

Personal anecdote and media commentary, not clinical evidence. For educational purposes only.

"Everyday, countless hours of physical therapy, peptide injections, iv drips and pushes, stem cell and exosomes, red light / IR therapy."

Jeremy Renner, in a 2023 Instagram post detailing his recovery regimen following the January 2023 snowplow accident in which he broke 30 bones. Renner has publicly named BPC-157, Thymosin Alpha-1, Thymosin Beta-4, and MOTS-c as peptides in his recovery protocol. Coverage in NBC News and The Hollywood Reporter.

Personal anecdote, not clinical evidence. For educational purposes only.

Want to go deeper? Mechanism, half-life, studied dosing, side effects, and the full reference list. Click to expand.

Background and what TB-500 actually is

Thymosin Beta-4 is a naturally occurring 43-amino-acid protein found in essentially every cell of the human body. It plays a central role in actin polymerization, the assembly of the cellular skeleton that allows cells to move and reorganize. It's involved in wound healing, cardiac repair, and various forms of tissue remodeling.

"TB-500" is a synthetic 17-amino-acid peptide corresponding to amino acids 17-23 of Thymosin Beta-4 (the LKKTETQ region), which contains much of the active actin-binding domain. Most "TB-500" research-peptide products are this fragment. The full Thymosin Beta-4 protein has been investigated by RegeneRx Biopharmaceuticals in clinical trials for various indications, with mixed results.

Mechanism of action

Actin sequestration and cell migration

The active region of Thymosin Beta-4 binds and sequesters G-actin monomers, regulating the dynamic assembly and disassembly of actin filaments. This influences cytoskeletal dynamics and is the basis for the peptide's role in cell migration during tissue repair.

Angiogenesis

Promotes formation of new blood vessels in animal injury and wound-healing models, a feature that complements BPC-157's similar effect in the rationale for the Wolverine combination.

Anti-inflammatory effects

Multiple animal studies report reduction in inflammatory markers and pro-inflammatory cytokines in injured tissues following Thymosin Beta-4 administration.

Cardiac and ophthalmic repair

Animal models of myocardial infarction and corneal injury show enhanced repair, motivating the early clinical trials in cardiology and ophthalmology that did not advance to approval.

Commonly studied dosing protocols

These are not recommendations. Safe and effective doses in humans have not been established. Always consult a licensed healthcare provider.

Subcutaneous (research range): 2 to 5 mg per dose, typically given one to two times per week. Some research-community protocols front-load with twice-weekly dosing for 4 to 6 weeks, then drop to weekly maintenance.

Treatment duration: typical research-community cycle ranges are 4 to 8 weeks. Long-term safety in healthy adults using TB-500 has not been characterized.

Half-life and pharmacokinetics

Animal data suggest a relatively long systemic presence, hours to a day or more, which is the rationale behind the once-or-twice-weekly research-community dosing. Human pharmacokinetics for the synthetic 17-amino-acid fragment have not been formally characterized.

Side effects and safety profile

Reported in research and community settings: mild injection-site redness or tenderness; transient lethargy or "flu-like" feeling shortly after a dose (uncommon); mild headache. Long-term safety data does not exist for the synthetic fragment. RegeneRx's clinical trials of full-length Thymosin Beta-4 reported a generally favorable tolerability profile in the populations studied, but those trials are not directly comparable to the synthetic-fragment use case discussed in research-peptide circles.

Theoretical concerns: any peptide that promotes angiogenesis carries theoretical concerns about effects on tumor biology. There are no reports of TB-500 promoting tumor growth, but the question has not been adequately studied.

References

Goldstein AL, Hannappel E, Sosne G, Kleinman HK. (2012). "Thymosin β4: a multi-functional regenerative peptide." Expert Opin Biol Ther, 12(1), 37–51. PubMed
Malinda KM, Sidhu GS, Mani H, et al. (1999). "Thymosin beta4 accelerates wound healing." J Invest Dermatol, 113(3), 364–368. PubMed
Philp D, Kleinman HK. (2010). "Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide." Ann N Y Acad Sci, 1194, 81–86. PubMed
Bock-Marquette I, Saxena A, White MD, et al. (2004). "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature, 432(7016), 466–472. PubMed
Sosne G, Qiu P, Goldstein AL, Wheater M. (2010). "Biological activities of thymosin beta4 defined by active sites in short peptide sequences." FASEB J, 24(7), 2144–2151. PubMed
U.S. Food and Drug Administration. (2023). "Pharmacy Compounding Guidance. FDA Category 2 List." FDA.gov

For educational and research purposes only. This is not medical advice. TB-500 is not FDA-approved and is on the FDA's Category 2 list as of September 2023. Consult a licensed healthcare provider before considering any peptide. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does. Information current as of May 2026.